NervGen Pharma (9UA) Price & Analysis

3 Followers

9UA Stock Chart & Stats

€3.50

-€0.04(-2.08%)

At close: Jan 08 4:00 PM EST

€3.50

-€0.04(-2.08%)

Day’s Range― - ―

52-Week Range€1.34 - €5.00

Previous CloseN/A

Volume2.00

Average Volume (3M)821.00

Market Cap

€113.53M

Enterprise Value€289.36

Total Cash (Recent Filing)€16.55M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.34

Next Earnings

Aug 12, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding82,193,140

10 Day Avg. Volume1,284

30 Day Avg. Volume821

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)159.85

Price to Sales (P/S)0.00

P/FCF Ratio-28.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€8.98

Price Target Upside156.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.21

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy SignalIndependent, blinded biomechanical gait analyses showed statistically significant, multi-domain recovery in chronic tetraplegia patients, providing objective evidence that NVG-291 can restore function long after injury. This durable efficacy signal materially de-risks the clinical program and supports a credible path to registration and first-mover positioning in neuroreparative therapy.

Regulatory ProgressAlignment with the FDA at an End-of-Phase 2 meeting and a defined plan for the RESTORE registrational study reduces regulatory uncertainty and clarifies endpoints and trial design. This structural milestone improves predictability for a development timeline and strengthens the company’s ability to execute a registrational Phase 3 program and engage partners.

Access To Capital MarketsA successful underwritten offering and subsequent ATM program demonstrate institutional capital-market access, extending development runway for NVG-291. Structural access to equity markets and documented investor support provide flexibility to fund late-stage trials, site activations and regulatory activities without immediate operational trade-offs.

Bears Say

Pre-revenue Loss ProfileThe company remains pre-revenue with materially negative operating results and large cash burn. Persistent losses and negative operating cash flow create a structural funding gap between development needs and internal cash generation, increasing execution risk for long, costly Phase 3 studies absent sustained financing.

Dependence On External FinancingAlthough leverage is low, historical negative equity in 2023 and recurring capital raises show structural reliance on external funding. Future program continuity and timelines are tied to capital markets capacity; adverse market conditions or tighter terms could force dilution, slow development, or require partnership concessions.

Concentrated, Small-Scale OperationsA very small employee base and a single lead candidate concentrate operational and pipeline risk. Long-term execution for a registrational trial and eventual commercialization will require substantial scaling, outsourcing and hiring. This structural constraint increases dependency on CROs/partners and heightens vulnerability if NVG-291 setbacks occur.

NervGen Pharma News

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18...

18d ago

NGEN

NervGen Pharma initiated with an Outperform at Leerink

Leerink analyst Marc Goodman initiated coverage of NervGen Pharma (NGEN) with an Outperform rating and $10 price target...

18d ago

NGEN

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

NervGen Pharma ( ($NGEN) ) has issued an update. On July 2, 2026, NervGen Pharma filed a Form...

29d ago

NGEN

NervGen Pharma initiated with a Buy at TD Cowen

TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company...

2M ago

NGEN

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma priced an underwritten...

2M ago

NGEN

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A...

2M ago

NGEN

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

NervGen Pharma ( ($NGEN) ) has provided an update. On May 26, 2026, NervGen Pharma reported independently conducted,...

2M ago

NGEN

NervGen Pharma files $250M mixed securities shelf

09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

NGEN

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...

2M ago

NGEN

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma announced it had...

2M ago

NGEN

NervGen Pharma 24M share Spot Secondary priced at $2.50

Leerink and TD Cowen acted as joint book running managers for the offering. Published first on TheFly –...

2M ago

NGEN

NervGen Pharma secondary being re-offered at $2.50 per share

Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering. Published first on TheFly...

2M ago

NGEN

NervGen Pharma announces common share offering, no amount given

NervGen Pharma (NGEN) Corp. announced that it has commenced an underwritten public offering of common shares and accompanying...

2M ago

NGEN

NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows

NervGen Pharma ( ($NGEN) ) has provided an announcement. NervGen Pharma reported first-quarter 2026 results on May 18,...

2M ago

NGEN

9UA FAQ

What was Nervgen Pharma Corp’s price range in the past 12 months?

Nervgen Pharma Corp lowest stock price was €1.34 and its highest was €5.00 in the past 12 months.

What is Nervgen Pharma Corp’s market cap?

Nervgen Pharma Corp’s market cap is €113.53M.

When is Nervgen Pharma Corp’s upcoming earnings report date?

Nervgen Pharma Corp’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.

How were Nervgen Pharma Corp’s earnings last quarter?

Currently, no data Available

Is Nervgen Pharma Corp overvalued?

According to Wall Street analysts Nervgen Pharma Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nervgen Pharma Corp pay dividends?

Nervgen Pharma Corp does not currently pay dividends.

What is Nervgen Pharma Corp’s EPS estimate?

Nervgen Pharma Corp’s EPS estimate is -0.05.

How many shares outstanding does Nervgen Pharma Corp have?

Nervgen Pharma Corp has 82,193,140 shares outstanding.

What happened to Nervgen Pharma Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nervgen Pharma Corp?

Currently, no hedge funds are holding shares in DE:9UA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

NervGen Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

35.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nervgen Pharma Corp

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

NervGen Pharma (9UA) Earnings & Revenues

Historic Earnings Reports

9UA Stock 12 Month Forecast

Average Price Target

€8.98

▲(156.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.03110435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.976982996666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.21244174,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.765469565384615,3.620939130769231,4.476408696153846,5.331878261538462,6.187347826923077,7.042817392307692,7.898286957692308,8.753756523076923,9.609226088461538,10.464695653846153,11.32016521923077,12.175634784615385,{"y":13.03110435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.4536140766666663,2.997228153333333,3.540842229999999,4.084456306666666,4.628070383333332,5.171684459999999,5.7152985366666655,6.258912613333332,6.802526689999999,7.346140766666665,7.889754843333332,8.433368919999998,{"y":8.976982996666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.16403398,2.41806796,2.67210194,2.92613592,3.1801699,3.43420388,3.68823786,3.94227184,4.19630582,4.4503398,4.70437378,4.95840776,{"y":5.21244174,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >